Khemis A, et al. - In patients with non-segmental vitiligo, researchers conducted this 52 weeks prospective randomized placebo-controlled study to contrast the effectiveness of apremilast in combination therapy with narrowband (NB)-UVB vs placebo and NB-UVB treatment for repigmentation. Individuals who responded (decreased VASI > 30%) were re-randomized to receive apremilast or placebo after 24 weeks, combined with twice-weekly NB-UVB for 24 additional weeks. Eighty patients have been randomized. Apart from phototherapy, group A received apremilast at the label dosage and group B got the placebo. After an additional 24 weeks of treatment, no statistically significant differences were observed between the two groups. The authors concluded that apremilast does not produce any advantage to NB-UVB for treating vitiligo.